NCCN Guidelines for HR+ HER2 Metastatic Breast Cancer
2 Ansichten
administrator
07/03/23
Debu Tripathy, MD, and Hatem Soliman, MD, reflect on the NCCN guideline criteria and patient factors that play into decision making for frontline therapy in hormone receptor–positive metastatic breast cancer.
Zeig mehr
Facebook Kommentare
Keine Kommentare gefunden